
Soft tissue sarcoma drug receives FDA Orphan Designation
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Avacta Group’s chemotherapy drug, AVA6000, for the treatment of soft tissue sarcoma. AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using pre|CISION technology so that it is activated predominantly in… Read More















